Company: BIAF
Filing Date: 2025-05-02
Form Type: S-1
Source: 0001641172-25-008170
Chunk: 82

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-02
Form: S-1
Chunk 82
---
     | $     |   3,773,205 |   |     | $                  |   6,695,705 |   |
| Total capitalization                                                                                                                 |     | $                    |   2,602,036 |   |     | $     |   3,773,205 |   |     | $                  |   6,695,705 |   |

Each $0.10 increase (decrease) in the assumed public offering price of $0.499 per share of Common Stock and accompanying April 2025 Warrant, would increase (decrease) each of our pro forma, as adjusted cash and cash equivalents, additional paid-in capital, total stockholders’ equity (deficit) and total capitalization by approximately $645,000, assuming that the number of shares of Common Stock and accompanying April 2025 Warrants offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting Placement Agent fees and estimated offering expenses payable by us, and assuming no sale of any Pre-Funded Warrants in this offering, and no exercise of the April 2025 Warrants or Placement Agent Warrants being offered in this offering. Similarly, each increase (decrease) of 1,000,000 in the number of shares of Common Stock offered by us would increase (decrease) each of our pro forma, as adjusted cash, cash equivalents, additional paid-in capital, total stockholders’ equity (deficit) and total capitalization by approximately $459,000, assuming the assumed combined offering price of $0.499 per share of Common Stock and accompanying April 2025 Warrant remains the same and after deducting Placement Agent fees and estimated offering expenses payable by us, and assuming no sale of any Pre-Funded Warrants in this offering, no exercise of the April 2025 Warrants or Placement Agent Warrants being offered in this offering.

The information above is based on 15,576,674 shares of Common Stock outstanding as of December 31, 2024, and excludes, as of that date:

| ● | 12,298,124                                                                                         
 shares of Common Stock issuable upon the exercise of outstanding warrants with a weighted          
 average exercise price equal to $2.95 per share;                                                   |
| ● | 304,125                                                                                            
 shares                                                                                             
 of Common Stock issuable upon the exercise of stock options issued under our equity incentive      
 plans with a weighted average exercise price equal to